You have full text access to this OnlineOpen article

Is Ciprofloxacin a Substrate of P-glycoprotein?

  1. Miki Susanto Park PhD1,*,
  2. Hideaki Okochi PhD2,
  3. Leslie Z. Benet PhD2

Article first published online: 23 DEC 2010

DOI: 10.1111/j.1753-5174.2010.00032.x

Issue

Archives of Drug Information

Archives of Drug Information

Volume 4, Issue 1, pages 1–9, March 2011

Additional Information

How to Cite

Park, M. S., Okochi, H. and Benet, L. Z. (2011), Is Ciprofloxacin a Substrate of P-glycoprotein?. Archives of Drug Information, 4: 1–9. doi: 10.1111/j.1753-5174.2010.00032.x

Author Information

  1. 1

    Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA

  2. 2

    Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA

*Miki Susanto Park, PhD, Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, 751 Brookside Rd, Stockton, CA 95211, USA. Tel: (209) 946-3909; Fax: (209) 946-2160; E-mail: mpark@pacific.edu

  1. Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

Publication History

  1. Issue published online: 22 FEB 2011
  2. Article first published online: 23 DEC 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (790K)

References

  • 1
    Eliopoulos GM, Gardella A, Moellering RC Jr. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother 1984;25:331–5.
  • 2
    Sorgel F, Naber KG, Jaehde U, Reiter A, Seelmann R, Sigl G. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med 1989;87:62S–5S.
  • 3
    Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy 1990;36:77–84.
  • 4
    Parry MF, Smego DA, Digiovanni MA. Hepatobiliary kinetics and excretion of ciprofloxacin. Antimicrob Agents Chemother 1988;32:982–5.
  • 5
    Cavet ME, West M, Simmons NL. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1997;121:1567–78.
    Direct Link:
  • 6
    Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. Active intestinal elimination of ciprofloxacin in rats: Modulation by different substrates. Br J Pharmacol 1999;127:1728–34.
    Direct Link:
  • 7
    de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, et al. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 2000;12:85–93.
  • 8
    Griffiths NM, Hirst BH, Simmons NL. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br J Pharmacol 1993;108:575–6.
  • 9
    Lowes S, Simmons NL. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 2002;135:1263–75.
    Direct Link:
  • 10
    Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A 1988;85:4486–90.
  • 11
    Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97:1211–8.
  • 12
    Susanto M. Investigating the role of P-glycoprotein on drugs exhibiting enhanced renal clearance in cystic fibrosis patients. Thesis (Ph.D.), University of California San Francisco, San Francisco, CA2002.
  • 13
    Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res 2002;19:457–62.
  • 14
    Zhang Y, Benet LZ. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res 1998;15:1520–4.
  • 15
    Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 2008;74:122–31.
  • 16
    Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, et al. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol 2010;69:167–78.
    Direct Link:
  • 17
    Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001;296:723–35.
View Full Article (HTML) Get PDF (790K)